FindMyKOL
Clinical trialNCT04678154RecruitingPhase 3Interventional

Evaluation of a New Strategy for Protocolized Antibiotic Care for Severe Open Fractures: SEXTANT 2

SponsorMajor Extremity Trauma Research ConsortiumEnrollment600Post Operative Surgical Site Infection
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The PRCT evaluates infection outcomes as well as fracture and antibiotic-related complications to include the emergence of resistant bacteria associated with two different antibiotic strategies in the treatment of Gustilo type IIIB tibia and hindfoot fractures (calcaneus and talus) and selected IIIA fractures of the tibia and trauma-related transtibial amputations that are performed in the "zone-of-injury". This study will be conducted in established METRC level 1 trauma centers. The patients will be randomized as close to admission as possible to either 1) Standard of Care (SOC) prophylactic open fracture protocol, including the use of topical antibiotic as per the usual practice of the surgeon or 2) experimental protocol (SEXTANT). The SEXTANT protocol includes application of wound bioburden-targeted topical Vancomycin powder and Tobramycin powder antibiotic treatment at the time of final wound closure/coverage combined with 72 hours of systemic antibiotic coverage targeted to both gram-positive and gram-negative pathogens. The study will compare the results of the current SOC prophylactic coverage to the strategic wound bioburden treatment (SEXTANT) protocol. Up until the time of definitive wound closure/coverage, all patients will be treated per the usual regimen of the surgeon / center and in accordance with current Trauma Quality Improvement Program (TQIP) and Surgical Quality Improvement Program (SQIP) recommendations for the care of open fractures.14,15,17 It includes the administration of systemic antibiotics as close to the time of injury as possible. In the definitive wound closure/coverage procedure post-operative period, participants in the intervention arm will receive 72 hours of systemic antibiotic therapy targeted at the modern wound bioburden, and patients in the usual care arm will receive post-operative care per the usual practice of their surgeon. All other activities related to follow-up and related treatments will proceed per the usual practice of the surgeon.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

31 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Stanford University

    Redwood City, California, United States

    Recruiting
  • University of California at San Francisco

    San Francisco, California, United States

    Saam Morshed, MD
    Recruiting
  • _university of California, San Francisco

    San Francisco, California, United States

    Recruiting
  • University of Colorado Anschutz Medical Campus

    Aurora, Colorado, United States

    Recruiting
  • St Mary'S University/tenent Health

    West Palm Beach, Florida, United States

    Recruiting
  • Emory University School of Medicine

    Atlanta, Georgia, United States

    William Reisman, MD
    Recruiting
  • Indiana University School of Medicine - Methodist Hospital

    Indianapolis, Indiana, United States

    Recruiting
  • Indiana University/eskenazi Health

    Indianapolis, Indiana, United States

    Recruiting
  • University of Kentucky

    Lexington, Kentucky, United States

    Recruiting
  • Lsu Health Sciences

    New Orleans, Louisiana, United States

    Recruiting
  • University of Maryland , Md Department of Orthopaedics

    Baltimore, Maryland, United States

    Robert O'Toole, MD
    Recruiting
  • Walter Reed Military Medical Center

    Bethesda, Maryland, United States

    Recruiting
  • Harvard/mass General/brigham Hospitals

    Boston, Massachusetts, United States

    Recruiting
  • Hennepin County Medical Center / Minneapolis

    Minneapolis, Minnesota, United States

    Andrew Schmidt, MD
    Recruiting
  • University of Mississippi Medical Center

    Jackson, Mississippi, United States

    Recruiting
  • Dartmouth Hitchcock

    Lebanon, New Hampshire, United States

    Recruiting
  • Jamaica Hospital Medical Center

    Jamaica, New York, United States

    Sanjit Konda, MD
    Recruiting
  • University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina, United States

    Recruiting
  • Atrium Health Carolinas Medical Center

    Charlotte, North Carolina, United States

    Recruiting
  • Atrium Health Wake Forest Baptist

    Winston-Salem, North Carolina, United States

    Recruiting
  • Metrohealth

    Cleveland, Ohio, United States

    Recruiting
  • Ohio State University Wexner Medical Center

    Columbus, Ohio, United States

    Recruiting
  • University of Oklahoma College of Medicine

    Oklahoma City, Oklahoma, United States

    Recruiting
  • Temple University

    Philadelphia, Pennsylvania, United States

    Recruiting
  • Brown University/rhode Island Hospital

    Providence, Rhode Island, United States

    Roman Hayda, MD
    Recruiting
  • Rhode Island Hospital/brown University

    Providence, Rhode Island, United States

    Recruiting
  • Vanderbilt University Medical Center

    Nashville, Tennessee, United States

    William T. Obremskey, MD
    Recruiting
  • University of Texas Health Science Center - Houston

    Houston, Texas, United States

    Stephen Warner, MD
    Recruiting
  • University of Virginia

    Charlottesville, Virginia, United States

    David Weiss, MD
    Recruiting
  • Inova Fairfax Medical Campus

    Falls Church, Virginia, United States

    Recruiting
  • Virginia Commonwealth University Medical Center

    Richmond, Virginia, United States

    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Standard of CareVancomycin and Tobramycin
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
7 May 2021
Primary completion
30 Sept 2028
Completion
31 Mar 2029
Last update posted
22 Jul 2026
Registered enrollment
600
Registry id
NCT04678154

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 18 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.